Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 12 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoSorbents Corporation | CTSO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.801 | 04:40:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.801 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 12 | - | 0.782 - 4.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:00 | 12 | $ 0.8499 | USD |
CytoSorbents Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 35.55M | 44.44M | - | 36.35M | -28.51M | -0.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytoSorbents News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTSO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.89 | 0.96 | 0.782 | 0.8225527 | 85,683 | -0.089 | -10.00% |
| 1 Month | 0.8601 | 1.02 | 0.782 | 0.9119573 | 88,106 | -0.0591 | -6.87% |
| 3 Months | 0.8832 | 1.06 | 0.782 | 0.957231 | 100,897 | -0.0822 | -9.31% |
| 6 Months | 1.60 | 2.15 | 0.782 | 1.14 | 231,413 | -0.799 | -49.94% |
| 1 Year | 3.09 | 4.29 | 0.782 | 1.53 | 150,079 | -2.29 | -74.08% |
| 3 Years | 9.02 | 9.80 | 0.782 | 3.79 | 190,252 | -8.22 | -91.12% |
| 5 Years | 7.21 | 13.89 | 0.782 | 6.05 | 269,204 | -6.41 | -88.89% |
CytoSorbents Description
| CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany. |
